671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer

• Carl H June,
• Joseph A Fraietta,
• Gabriela Plesa,
• Amy Marshall,
• Mark H O’Hara,
• Janos L Tanyi,
• Elizabeth Hexner,
• Julie Jadlowsky,
• Matthew Ferrara,
• Olivia Farrelly,
• Adam Runkle,
• Anne Chew,
• Emily Dowd,
• Vanessa Gonzalez,
• Neil C Sheppard

Affiliations

Carl H June

6Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

Joseph A Fraietta

1Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

Gabriela Plesa

Aff10 grid.25879.310000000419368972University of Pennsylvania Blue Bell PA USA

Amy Marshall

Adelaide Nursing School, The University of Adelaide, Adelaide, South Australia, Australia

Mark H O’Hara

2University of Pennsylvania, Philadelphia, PA, USA

Janos L Tanyi

1University of Pennsylvania, Media, PA, USA

Elizabeth Hexner

2University of Pennsylvania, Philadelphia, PA, USA

Julie Jadlowsky

2University of Pennsylvania, Philadelphia, PA, USA

Matthew Ferrara

2University of Pennsylvania, Philadelphia, PA, USA

Olivia Farrelly

2University of Pennsylvania, Philadelphia, PA, USA

Adam Runkle

2University of Pennsylvania, Philadelphia, PA, USA

Anne Chew

2University of Pennsylvania, Philadelphia, PA, USA

Emily Dowd

2University of Pennsylvania, Philadelphia, PA, USA

Vanessa Gonzalez

2University of Pennsylvania, Philadelphia, PA, USA

Neil C Sheppard

2University of Pennsylvania, Philadelphia, PA, USA